Evercore ISI analyst Liisa Bayko upgraded Crispr Therapeutics (CRSP) to Outperform from In Line with a price target of $99, up from $60. Upcoming key catalysts could “usher in a new era,” says the analyst, whose increased price target now includes the addition of in vivo programs CTX320 and CTX310 with 10% and 5% odds of success, respectively, applied for the programs.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRSP:
- CRISPR Therapeutics Reports 2024 Results and Clinical Progress
- Crispr Therapeutics price target lowered to $49 from $53 at Stifel
- Q4 Earnings Surprise Greenlights CRISPR Therapeutics Stock Climb
- Promising Growth Prospects for Crispr Therapeutics AG: Buy Rating Affirmed by Kostas Biliouris
- Crispr Therapeutics Faces Market Challenges Amidst BPCIA Biosimilar Risks